Bausch & Lomb Corp (BLCO)
Sector: Healthcare
Industry: Ophthalmic Goods
Country: Canada
Exchange: NYSE
Market cap: $6.02B
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Latest financial period: June 30, 2026
Filed with the SEC: July 29, 2026
Estimated earnings date: November 4, 2026
Profit #1225 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROIC | 1.6% | 1.3% | 0.9% | 0.7% |
Growth #368 of 1484 companies
Payout #1117 of 1484 companies
Safety #1015 of 1484 companies
Price #1277 of 1484 companies
